Trial profile

Luc F Van Gaal, Lancet 2005;365:1389

Baseline characteristics

Luc F Van Gaal, Lancet 2005;365:1389

Change from baseline in bodyweight (A)

and waist circumference (B)

Luc F Van Gaal, Lancet 2005;365:1389

A B

Changes in metabolic and cardiovascular risk factors in ITT

population Part I

Luc F Van Gaal, Lancet 2005;365:1389

Luc F Van Gaal, Lancet 2005;365:1389

Changes in metabolic and cardiovascular risk factors in ITT

population Part II

Luc F Van Gaal, Lancet 2005;365:1389

Changes in metabolic and cardiovascular risk factors in ITT

population Part III

Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part I

Luc F Van Gaal, Lancet 2005;365:1389

Luc F Van Gaal, Lancet 2005;365:1389

Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part II

Luc F Van Gaal, Lancet 2005;365:1389

Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part

III

Proportion of patients who lost 5% and

10% of baseline weight at 1 year

Luc F Van Gaal, Lancet 2005;365:1389

*p<0.001 vs placebo. †p=0.002 vs placebo.

Mean percentage change from baseline

in HDL-cholesterol (A) and triglycerides (B)

Luc F Van Gaal, Lancet 2005;365:1389

*p<0.001 vs placebo. †p=0.002 vs placebo.

Prevalence of the metabolic syndrome

in the ITT and completer populations at baseline and after 1 year of

treatment

Luc F Van Gaal, Lancet 2005;365:1389

Patients reporting adverse events (≥5% in any treatment group)

Luc F Van Gaal, Lancet 2005;365:1389

Serious adverse events by system organ class

during the double-blind period of the trial

Luc F Van Gaal, Lancet 2005;365:1389

Patients reporting adverse events leading to discontinuation

Luc F Van Gaal, Lancet 2005;365:1389

Hypothetical model of role of central and peripheral components of

endocannabinoid system in regulation of food intake and peripheral metabolism

Luc F Van Gaal, Lancet 2005;365:1389